AbbVie Inc. Stock
€196.80
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
3 Exceptional Stocks to Build Long-Term Wealth
With many stocks looking overvalued, many investors may be tempted to sell. However, there are several factors to consider before taking profits:
- Time horizon – when an investor will need the
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do so. The AbbVie stock price is in a sustained uptrend
2 Dividend Stocks to Double Up on Right Now
Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining
Carolina Wealth Trims It's AbbVie Stake to Nearly Nothing
Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79
Why AbbVie Stock Soared in September
Any pharmaceutical company as large and sprawling as AbbVie (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications
3 Dividend Stocks to Double Up On Right Now
If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing. For example, you might regret eating two giant helpings of ice cream rather than one. However, in many
St Louis Financial Loads Up on AbbVie (ABBV) With 14,600 Shares Buy
St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (NYSE:ABBV), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.
According to a Securities and
Why AbbVie Stock Cruised to an Almost 6% Gain Today
The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (NYSE: ABBV) stock on Wednesday. The pharmaceutical company's shares rose by
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Stocks in the S&P 500 (SNPINDEX: ^GSPC) offer a miserly yield of 1.2% (on average) today. You can do way better than that and still invest in very attractive businesses. To prove that out, just look
Where Will AbbVie Be in 5 Years?
AbbVie (NYSE: ABBV) ranks as the third-largest pharmaceutical company in the world, with a market capitalization hovering around $390 billion. It markets around a dozen blockbuster drugs, plus many
1 Top Dividend Stock to Buy and Hold Forever
Strong dividend payers can be a stabilizing force in a well-diversified portfolio. That's because corporations that can consistently pay and raise their payouts over a long period are often
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
It isn't easy to find a pharmaceutical company that has a strong product lineup and a robust pipeline, but also cranks out a generous dividend every quarter. I've been an AbbVie (NYSE: ABBV) bull
3 No-Brainer Dividend Stocks to Buy in September
Some decisions are tough to make. Others are so easy that they don't require much thought and are practically no-brainers.
Three Motley Fool contributors believe they've identified dividend stocks
1 Green Flag for AbbVie (ABBV) Stock Right Now
AbbVie (NYSE: ABBV) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the
Why AbbVie Stock Is Jumping Today
Shares of AbbVie (NYSE: ABBV) were jumping 4.2% higher as of 11:37 a.m. ET on Thursday. The nice gain came after the big drugmaker revealed that it had settled litigation with all companies that
1 Reason Every Investor Should Know About AbbVie (ABBV)
With patent-protected market exclusivity for their products, pharmaceutical companies reliably produce profits that they aren't shy about distributing to shareholders. In an industry already known
3 Stocks to Buy and Hold Forever
What's one of the biggest mistakes investors make? Selling stocks too soon. It's smarter to try to adhere to Warren Buffett's favorite holding period of "forever," or at least as close to that goal
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate
3 Stocks Retirees Should Absolutely Love
Priorities change as you enter new seasons of life. That's especially true for your retirement years. And the changing priorities can include what you want from your investments. Income usually
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
Think back to 10 years ago. The New England Patriots and their quarterback Tom Brady were accused of underinflating footballs. The Supreme Court affirmed same-sex marriage nationwide. And Apple
3 Unstoppable Stocks to Buy in August
The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable.
Three Motley Fool contributors believe they've found such unstoppable stocks with the
Why AbbVie Stock Flew Higher on Friday
A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (NYSE: ABBV) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in